An Intra-Individual Comparison of MRI, [18F]-FET and [18F]-FLT PET in Patients with High-Grade Gliomas
Open Access
- 23 April 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (4), e95830
- https://doi.org/10.1371/journal.pone.0095830
Abstract
Intra-individual spatial overlap analysis of tumor volumes assessed by MRI, the amino acid PET tracer [18F]-FET and the nucleoside PET tracer [18F]-FLT in high-grade gliomas (HGG). MRI, [18F]-FET and [18F]-FLT PET data sets were retrospectively analyzed in 23 HGG patients. Morphologic tumor volumes on MRI (post-contrast T1 (cT1) and T2 images) were calculated using a semi-automatic image segmentation method. Metabolic tumor volumes for [18F]-FET and [18F]-FLT PETs were determined by image segmentation using a threshold-based volume of interest analysis. After co-registration with MRI the morphologic and metabolic tumor volumes were compared on an intra-individual basis in order to estimate spatial overlaps using the Spearman's rank correlation coefficient and the Mann-Whitney U test. [18F]-FLT uptake was negative in tumors with no or only moderate contrast enhancement on MRI, detecting only 21 of 23 (91%) HGG. In addition, [18F]-FLT uptake was mainly restricted to cT1 tumor areas on MRI and [18F]-FLT volumes strongly correlated with cT1 volumes (r = 0.841, p18F]-FET PET detected 22 of 23 (96%) HGG. [18F]-FET uptake beyond areas of cT1 was found in 61% of cases and [18F]-FET volumes showed only a moderate correlation with cT1 volumes (r = 0.573, p18F]-FET compared to [18F]-FLT tracer uptake (8.3 vs. 2.7 cm3, p18F]-FET but not [18F]-FLT PET was able to detect metabolic active tumor tissue beyond contrast enhancing tumor on MRI. In contrast to [18F]-FET, blood-brain barrier breakdown seems to be a prerequisite for [18F]-FLT tracer uptake.This publication has 48 references indexed in Scilit:
- POSITRON EMISSION TOMOGRAPHY-GUIDED VOLUMETRIC RESECTION OF SUPRATENTORIAL HIGH-GRADE GLIOMASNeurosurgery, 2009
- Association of 11C-Methionine PET Uptake With Site of Failure After Concurrent Temozolomide and Radiation for Primary Glioblastoma MultiformeInternational Journal of Radiation Oncology*Biology*Physics, 2009
- [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade gliomaRadiation Oncology, 2008
- The Role of Human Nucleoside Transporters in Uptake of 3′-Deoxy-3′-fluorothymidineMolecular Pharmacology, 2008
- 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed gliomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Glioma Proliferation as Assessed by 3‘-Fluoro-3’-Deoxy-l-Thymidine Positron Emission Tomography in Patients with Newly Diagnosed High-Grade GliomaClinical Cancer Research, 2008
- Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomasJournal of Neuro-Oncology, 2008
- Axl and Growth Arrest–Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma MultiformeClinical Cancer Research, 2008
- Spatial Heterogeneity of Low-Grade Gliomas at the Capillary Level: A PET Study on Tumor Blood Flow and Amino Acid UptakeJournal of Nuclear Medicine, 2007
- Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas.2006